Precigen (NASDAQ:PGEN) Price Target Raised to $9.00

Precigen (NASDAQ:PGEN) had its target price raised by Citizens Jmp from $8.00 to $9.00 in a report released on Thursday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

PGEN has been the topic of several other reports. HC Wainwright increased their price objective on Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Finally, Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.50.

Precigen Price Performance

Shares of PGEN opened at $3.67 on Thursday. The company has a market cap of $1.30 billion, a P/E ratio of -2.74 and a beta of 1.10. Precigen has a fifty-two week low of $1.11 and a fifty-two week high of $5.47. The company has a quick ratio of 3.95, a current ratio of 3.09 and a debt-to-equity ratio of 4.46. The firm’s 50 day moving average price is $4.08 and its 200 day moving average price is $3.97.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.09. The company had revenue of $4.57 million during the quarter, compared to analysts’ expectations of $8.29 million. Precigen had a negative net margin of 2,588.21% and a positive return on equity of 2,317.96%. On average, research analysts forecast that Precigen will post -0.32 earnings per share for the current fiscal year.

Institutional Trading of Precigen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Xponance LLC raised its stake in Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,993 shares during the last quarter. Composition Wealth LLC increased its holdings in shares of Precigen by 16.5% in the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 3,000 shares during the period. Intech Investment Management LLC increased its holdings in shares of Precigen by 5.2% in the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 3,137 shares during the period. Finally, Strs Ohio raised its stake in shares of Precigen by 6.8% during the third quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,200 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.